Kraft Group has contributed funds to an ElMinda funding round that will support continued development of a medical device to measure brain function.

Israel-based biotechnology company ElMinda closed an oversubscribed series C round featuring diversified conglomerate Kraft Group at $28m yesterday.

Investment bank WR Hambrecht, asset manager Palisade Capital Management, and investment advisers Healthcrest and Wexford Capital also supported the round, as did undisclosed additional backers.

Crowdfunding service OurCrowd has also been named as an investor, and records show Elminda secured $2m through the platform. However, that fundraising is not dated and it remains unclear whether the capital is part of the series…